We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The MHRA has reviewed the latest evidence relating to the very rare risk of PRES and RCVS associated with medicines containing pseudoephedrine
Information for manufacturers of medical devices about reporting adverse incidents and field safety corrective actions to the MHRA.
Urgent safety updates arising from pharmacovigilance data, including reported adverse events, for veterinary medicines authorised in the UK.
Guidance on managing and using bed rails safely.
How investigators and sponsors should manage clinical trials during COVID-19
Organisational definitions of terms concerned with risk and risk-related matters.
Information for public health professionals on immunisation.
Change your protocol, update your authorisation, report safety issues, submit safety updates and complete your end-of-trial study report.
Advises on how planning can manage potential noise impacts in new development.
Provides clarity on the need for sustainability appraisal and strategic environmental assessment in relation to plan development.
The review of the safety of isotretinoin has concluded.
When a material is waste, is a by-product or meets ‘end of waste’ status.
How marketing authorisation holders should inform MHRA of a signal or an ADR to a medicine.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Healthcare professionals prescribing fluoroquinolone antibiotics (ciprofloxacin, delafloxacin, levofloxacin, moxifloxacin, ofloxacin) are reminded to be alert to the risk of disabling and potentially long-lasting or irreversible side effects. Do not prescribe fluoroquinolones for non-severe or self-limiting infections, or for mild to...
Guidance for Marketing Authorisation Holders and holders of other types of authorisations on their responsibilities for veterinary pharmacovigilance and how to report suspected Adverse Events.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).